Hungarian Gedeon Richter and Irish Allergan are staying on course in the face of dissappointing Phase III results for depression drug cariprazine. The partners will now begin another Phase III study needed for approval.

Araclon Biotech’s Alzheimer’s vaccine ABvac40 is going forward into Phase II after showing a good safety profile in Phase I. The promising trial results were presented at the Alzheimer’s Association International Conference. 

After a two-year pilot period, the EMA has published its report on its adaptive pathways approach. The agency plans to explore the concept further and will continue to accept proposals.

US- and UK-based genomics company Inivata has appointed Timothy Shannon as Chief Financial Officer. Shannon joins Inivata fom Baxano Surgical, where he held the position of CFO and treasurer.

Philippe Dro is taking over the helm of NeMoDevices AG, a Switzerland-based developer in the innovative monitoring of brain blood flow and oxygen levels. The previous CEO Michael Oberle will serve as COO in future.

Life science venture capital group Epidarex has launched Nodthera Ltd, a biotech based on research by Poland-based drug discovery company Selvita. The start-up aims to develop novel inhibitors of the NLRP3 inflammasome. 

GlaxoSmithKline has in-licensed Janssen’s anti-IL-33R monoclonal antibody for severe asthma. The British drugmaker is paying €208m up front for the mAb.

In view of the Brexit, research academies across Britain are calling for a bold commitment from the government. The Royal Society President urges the UK government to underwrite the research of British scientists applying for EU funding.

JANUS® Automation Workstations deliver real-time and future adaptability in throughput, capacity, and dynamic volume range from 0.5 ?l to 5000 ?l for consistent and reproducible sample preparation 

Swedish rare disease expert Wilson Therapeutics AB has appointed global regulatory executive Rick Lilley as Chief Regulatory Officer.